This article originally posted 23 January, 2007 and appeared in Issue 348
C-Peptide Replacement Improves Early Diabetic Neuropathy
C-peptide improves sensory nerve function in type 1 diabetic patients with early-stage diabetic neuropathy.
Advertisement
Dr. Karin Ekberg from the Karolinska Institute, Stockholm, Sweden stated that,
"In contrast to what was previously the prevailing view, C-peptide is in
fact a bioactive peptide and its effect may well be of importance for the maintenance
of microvascular function." "Thus, C-peptide deficient patients, i.e.,
type 1 diabetes patients, should receive replacement of C-peptide probably already
from the onset of the disease."
Dr. Ekberg and colleagues examined whether 6 months of treatment with C-peptide
improved sensory nerve conduction velocity and other early signs of diabetic
neuropathy in the lower extremities of 139 type 1 diabetic patients. They were
randomized to low-dose C-peptide at 1.5 mg per day in four divided subcutaneous
doses, to a 3-times higher dose, or placebo
At baseline, both sensory and motor nerve conduction velocities were significantly
reduced compared with normal, the results indicate.
After 6 months of treatment, peak sensory nerve conduction velocities improved
in the groups treated with low-dose or high-dose C-peptide, but not significantly
compared with the control group, the researchers report.
However, significantly more patients treated with C-peptide (37%) than patients
in the control group (19%) experienced a peak sensory nerve conduction velocity
improvement of at least 1 meter/second, the investigators found.
Among patients with the least affected nerve conduction velocity at baseline,
improvements in sensory nerve conduction velocity were significantly better
among those treated with C-peptide, the researchers say.
Vibration perception threshold and neuropathy impairment assessment also improved
in the C-peptide treatment group compared with the placebo group, but motor
conduction velocities decreased in both groups during the study.
"C-peptide may be beneficial not only for nerve function, but also for
the treatment and prevention of other diabetes-induced long-term complications
of type 1 diabetes," Dr. Ekberg said. "There are clinical and pre-clinical
data to indicate that C-peptide administration serves to ameliorate both functional
and structural abnormalities in type 1 diabetic nephropathy."
The group plans "to continue the pharmaceutical development of C-peptide
with phase III clinical studies in order to demonstrate the safety and efficacy
of C-peptide replacement therapy for the treatment of diabetic peripheral neuropathy,"
Dr. Ekberg added. "Such studies will include a larger patient population
and a treatment duration of at least 12 months."
Diabetes Care 2007;30:71-76.
===============================
FACT:
Every minute across the world, 6 people die of diabetes... Either directly,
or indirectly as the result of a complication. In total this disease is therefore
the cause of almost 4 million deaths per year! Which is as many as those caused
by AIDS. These are the figures put forward by the World Health Organization
and the International Diabetes Federation (the IDF). It's a genuine massacre
which shows no sign of stopping.
DISCLAIMER: The content of this Website is independent of the views of our advertisers and sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.
Copyright @ 1999-2010 Diabetes In Control, Inc.. All rights reserved.